Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples...

Full description

Bibliographic Details
Main Authors: Daniel S. Graciaa, Hans P. Verkerke, Jeannette Guarner, Ana Maria Moldoveanu, Narayanaiah Cheedarla, Connie M. Arthur, Cheryl L. Maier, Andrew Neish, Sara C. Auld, Angie Campbell, Neel R. Gandhi, John D. Roback, N. Sarita Shah
Format: Article
Language:English
Published: Cambridge University Press 2022-01-01
Series:Antimicrobial Stewardship & Healthcare Epidemiology
Online Access:https://www.cambridge.org/core/product/identifier/S2732494X22002984/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S2732494X22002984/type/journal_article

Similar Items